Great news, finally.
I was wondering about what numbers we could be seeing with both the Eisai partnership and the ERT partnership.
I understand that there is huge potential here, but it's not as if the company has been profitable, right? How should one think about it?
If we divide those $45 Million from Eisai by 10 years, we're talking about $4,5 Million per year. Let's say that it's all profit and slap a 20x multiple on it. That would mean a AUD$126 Million marketcap. The current marketcap is $206 Million, so Mr Market is ascribing a AUD$80 Million value for the Clinical Trials and Research segments.
Is this too low? The administration costs have been consistently higher (or just a bit lower) than the operating profit from the Clinical Trials segment, so...
If Aducanumab doesn't go forward, should we expect a decline in Clinical Trials revenue?
Cheers
- Forums
- ASX - By Stock
- CGS
- Putting numbers on it
CGS
cogstate ltd
Add to My Watchlist
0.00%
!
$1.66

Putting numbers on it
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.66 |
Change
0.000(0.00%) |
Mkt cap ! $280.4M |
Open | High | Low | Value | Volume |
$1.69 | $1.70 | $1.64 | $66.74K | 39.86K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 2480 | $1.66 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.69 | 227 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 2480 | 1.660 |
1 | 189 | 1.640 |
2 | 5849 | 1.625 |
1 | 3000 | 1.620 |
1 | 621 | 1.610 |
Price($) | Vol. | No. |
---|---|---|
1.690 | 227 | 2 |
1.695 | 5579 | 1 |
1.700 | 2298 | 1 |
1.705 | 189 | 1 |
1.710 | 248 | 1 |
Last trade - 14.34pm 07/07/2025 (20 minute delay) ? |
Featured News
CGS (ASX) Chart |
The Watchlist
AGC
AUSTRALIAN GOLD AND COPPER LTD
Glen Diemar, MD
Glen Diemar
MD
SPONSORED BY The Market Online